Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections
Michael T Halpern1, Mary A Cifaldi, Jordana K Schmier
1Exponent, Health Sciences Group, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, USA. mhalpern@exponent.com
Abstract:
We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Modified-Release Drug Delivery Systems: Overview
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
IV Infusion to Oral Dosing: Conversion Methods
